| Nov 21 |
MoonLake Immunotherapeutics: A Somewhat Complicated Story
|
| Nov 13 |
MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis
|
| Nov 7 |
MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update
|
| Oct 13 |
MoonLake Immunotherapeutics: Lack Of Near Term Catalysts Makes It A Hold
|
| Oct 9 |
Biotechnology Value Fund L.P. Reduces Stake in MoonLake Immunotherapeutics
|
| Sep 25 |
Is MoonLake Immunotherapeutics (MLTX) the Best Guru Stock To Buy Now?
|
| Sep 23 |
MoonLake Immunotherapeutics (MLTX): Short Seller Sentiment is Bearish On This ADR Stock
|
| Sep 9 |
MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11
|
| Aug 28 |
MoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 Months
|
| Aug 26 |
MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts
|
